Literature DB >> 20019765

Retinal angiomatous proliferation or retinal anastomosis to the lesion.

A W Scott1, S B Bressler.   

Abstract

Much debate exists within the literature with respect to the variant of neovascular age-related macular degeneration (AMD) known as retinal angiomatous proliferation (RAP). We prefer the term retinal anastomosis to the lesion (RAL), as we believe that the choroidal neovascularization (CNV) lesion precedes the development of an anastomosing retinal vessel to this lesion. Natural history data surrounding RAP lesions are available through analysis of the eyes with subfoveal occult CNV within the placebo arm of the Verteporfin in Photodynamic Therapy (VIP) trial. Although many reports ascribe a poor prognosis to RAP lesions, the data suggest that the true natural history of RAP lesion may be highly variable and similar to that of other CNV lesions. Information from clinical trials suggests that the response of RAP lesions to CNV treatments may also be similar to that of other variants of neovascular AMD.

Entities:  

Mesh:

Year:  2009        PMID: 20019765     DOI: 10.1038/eye.2009.311

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  12 in total

1.  Three dimensional spectral domain optical coherence tomography features of retinal-choroidal anastomosis.

Authors:  Giuseppe Querques; Fernando O Avellis; Lea Querques; Nathalie Massamba; Francesco Bandello; Eric H Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-23       Impact factor: 3.117

2.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

Review 3.  Clinical characteristics and current treatment of age-related macular degeneration.

Authors:  Yoshihiro Yonekawa; Ivana K Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-03       Impact factor: 6.915

4.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

Review 5.  Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis.

Authors:  Mohammad Hossein Jabbarpoor Bonyadi; Mehdi Yaseri; Mortaza Bonyadi; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2016-12-22       Impact factor: 2.031

Review 6.  Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.

Authors:  Shiqi Yang; Jingke Zhao; Xiaodong Sun
Journal:  Drug Des Devel Ther       Date:  2016-06-02       Impact factor: 4.162

7.  Distinguishing retinal angiomatous proliferation from polypoidal choroidal vasculopathy with a deep neural network based on optical coherence tomography.

Authors:  Daniel Duck-Jin Hwang; Seong Choi; Junseo Ko; Jeewoo Yoon; Ji In Park; Joon Seo Hwang; Jeong Mo Han; Hak Jun Lee; Joonhong Sohn; Kyu Hyung Park; Jinyoung Han
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

8.  Unaffected fellow eye neovascularization in patients with type 3 neovascularization: Incidence and risk factors.

Authors:  Jae Hyuck Kwak; Woo Kyung Park; Rae Young Kim; Mirinae Kim; Young-Gun Park; Young-Hoon Park
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

Review 9.  Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration.

Authors:  Paris Tranos; Athanasios Vacalis; Solon Asteriadis; Stavrenia Koukoula; Athanasios Vachtsevanos; Georgia Perganta; Ilias Georgalas
Journal:  Drug Des Devel Ther       Date:  2013-06-17       Impact factor: 4.162

10.  MULTIMODAL EVIDENCE OF TYPE 3 NEOVASCULARIZATION IN ENHANCED S-CONE SYNDROME.

Authors:  Ramiro S Maldonado; Wadih M Zein; Catherine Cukras
Journal:  Retin Cases Brief Rep       Date:  2021-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.